XML 77 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations (Tables)
12 Months Ended
Dec. 31, 2021
Business Combinations [Abstract]  
Summary of Fair Values of Identifiable Net Assets

The final fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Austria as at the date of acquisition were as follows:

(in millions)

 

Fair value
recognized on
 acquisition
BioNTech R&D (Austria) GmbH

Assets

 

 

Intangible assets

 

€43.3

Other assets non-current and current

 

1.5

Total assets

 

€44.8

 

 

 

Liabilities

 

 

Other liabilities non-current and current

 

15.4

Total liabilities

 

€15.4

 

 

 

Total identifiable net assets at fair value

 

€29.4

 

 

 

Bargain purchase

 

                           (2.2)

Consideration transferred

 

€27.2

 

 

 

Consideration

 

 

Cash paid

 

21.7

Contingent consideration liability

 

5.5

Total consideration

 

€27.2

 

(in millions)

 

BioNTech R&D (Austria) GmbH

Transaction costs of the acquisition (included in cash flows from operating activities)

 

€(0.5)

Net cash acquired (included in cash flows used in investing)

 

0.9

Cash paid (included in cash flow used in investing activities)

 

                         (21.7)

Net cash flow on acquisition

 

€(21.3)

The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech US Inc. as at the date of acquisition were as follows:

 

(in millions)

 

Fair value
recognized on
acquisition
BioNTech US Inc.

Assets

 

 

Intangible assets

 

€29.9

Property, plant and equipment

 

5.6

Right-of-use assets

 

6.9

Other assets non-current and current

 

2.7

Cash and cash equivalents

 

7.7

Total assets

 

€52.8

 

 

 

Liabilities

 

 

Trade payables

 

1.7

Other liabilities non-current and current

 

17.8

Total liabilities

 

€19.5

 

 

 

Total identifiable net assets at fair value

 

€33.3

 

 

 

Goodwill from the acquisition

 

56.6

Consideration transferred

 

€89.9

 

 

 

Consideration

 

 

Shares issued, at fair value

 

€89.5

Cash paid

 

€0.4

Total consideration

 

€89.9

The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Manufacturing Marburg GmbH, or BioNTech Marburg, as at the date of acquisition were as follows:

(in millions)

 

Fair value
recognized on
acquisition
BioNTech Manufacturing Marburg GmbH

Assets

 

 

Property, plant and equipment

 

€79.8

Right-of-use assets

 

28.5

Inventories

 

2.4

Other assets non-current and current

 

4.3

Cash and cash equivalents

 

16.5

Total assets

 

€131.5

 

 

 

Liabilities

 

 

Provisions non-current and current

 

5.1

Trade payables

 

8.1

Other liabilities non-current and current

 

33.4

Total liabilities

 

€46.6

 

 

 

Total identifiable net assets at fair value

 

€84.9

 

 

 

Bargain purchase

 

  (7.0)

Consideration transferred

 

€77.9

 

 

 

Consideration

 

 

Cash paid

 

€77.9

Total consideration

 

€77.9